Annovis Bio, Inc. (ANVS) recently announced that its independent Data Safety Monitoring Board (DSMB) has officially approved the company to proceed with the pivotal Phase III clinical trial of Buntanetap for the treatment of Alzheimer's disease.

This key regulatory milestone paves the way for Annovis' clinical development program in the field of neurodegenerative diseases. Buntanetap, an oral small molecule drug, aims to slow the pathological progression of Alzheimer's disease by reducing levels of neurotoxic proteins. This Phase III trial will evaluate the drug's efficacy in improving cognitive function and its safety profile in patients with early-stage Alzheimer's disease. The DSMB's approval is based on a comprehensive review of Phase II clinical trial data, which showed that Buntanetap demonstrated significant efficacy on primary endpoints without major safety concerns. This decision means that the trial protocol meets ethical and scientific standards and can continue patient enrollment as planned. Annovis plans to conduct this randomized, double-blind, placebo-controlled Phase III study at multiple clinical centers worldwide, with an expected enrollment of approximately 450 patients. The company emphasized that this progress marks an important milestone for Buntanetap as a potential therapy for Alzheimer's disease.